Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with intestinal bowel disease in multiple sclerosis: a review.

Multiple sclerosis (MS) and inflammatory bowel disease (IBD) are autoimmune disorders characterized by inflammatory episodes affecting the brain and the gastrointestinal (GI) tract, respectively. The frequent association between MS and IBD suggests that both conditions may share common pathogenic mechanisms. However, different responses to biological therapies indicate differences in immune mechanisms of inflammation.